Drugs & Targets FDA Approves New Indications for Darzalex, Keytruda, Opdivo November 29, 2016Vol.39 No.10
Phase III Keytruda Study Shows Better OS vs. Chemo for Advanced Urothelial Cancer November 29, 2016Vol.39 No.10
Binimetinib plus encorafenib produces PFS improvement vs vemurafenib monotherapy November 29, 2016Vol.39 No.10
Drugs & Targets Genentech receives second Breakthrough Therapy Designation from FDA for Alecensa October 20, 2016Vol.39 No.09
Kyprolis Study in Newly Diagnosed Disease Doesn’t Meet Primary Endpoint—PFS October 20, 2016Vol.39 No.09
Novartis’s LEE011 + Letrozole Shows Superior PFS as First-Line Treatment for HR+/HER2- Advanced Breast Cancer October 20, 2016Vol.39 No.09
